肺结核
结核分枝杆菌
效应器
药物发现
计算生物学
生物
表型筛选
寄主(生物学)
疾病
表型
医学
生物信息学
免疫学
遗传学
基因
病理
作者
Arnaud Machelart,Ok‐Ryul Song,Eik Hoffmann,Priscille Brodin
标识
DOI:10.1016/j.drudis.2017.05.005
摘要
Tuberculosis (TB) remains a leading global health problem that is exacerbated by the emergence of multidrug and extensively drug-resistant Mycobacterium tuberculosis strains. Control of the disease requires novel therapeutic strategies. Modulating host homeostasis appears to be a promising approach, and recent studies have identified novel potential host targets and compounds that could be investigated for host-directed therapies (HDTs). Moreover, the recent development of intracellular high-throughput phenotypic assays makes it possible to screen large libraries of compounds to identify more rapidly new effectors for mycobacterial elimination. Technological advances combined with the novel HDT concept opens an interesting and promising research area that could ultimately deliver personalized TB treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI